275 results about "Uricacidemia" patented technology

The invention provides an animal bifidobacterium subsp. Lactis HNU329 with uric acid reducing ability and application thereof, the animal bifidobacterium subsp. Lactis HNU329 is preserved in Guangdong Microbiological Culture Collection Center GDMCC, the preservation address is Institute of Microbiology, Guangdong Academy of Sciences, on 5th floor, No. 59, No. 100 Courtyard, Xianlie Middle Road, Guangzhou, the preservation date is April 22, 2024, the preservation number is GDMCC No: 64546, and the preservation number is CGMCC No: 64546. The preparation method comprises the following steps of: classifying and naming Bifidobacteria animata subsp.lactis, and carrying out classification and naming on the Bifidobacteria animata subsp.lactis. The strain has good capacity of degrading nucleoside and purine in vitro, also shows good uric acid reducing capacity and anti-inflammatory capacity in animal model evaluation, and can regulate intestinal flora of mice with hyperuricemia and improve symptoms of hyperuricemia. The traditional Chinese medicine composition has no toxic or side effect, high safety and wide application prospect.

The invention discloses a tetrapeptide LILP with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tetrapeptide LILP is Leuu-Ile-Leu-Pro, and the amino acid sequence of the tetrapeptide LILP is shown in the specification. The invention discloses that the tetrapeptide LILP has uric acid reducing activity for the first time, and uric acid generation can be reduced by reducing the activity of xanthine oxidase in the liver; uric acid discharge can be increased by reducing kidney uric acid reabsorption. The invention provides a multi-target active substance for reducing uric acid, which can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of health-care foods for assisting in reducing the level of uric acid, and has a good application prospect.

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

The invention discloses a tripeptide LAF with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the tripeptide LAF is Leu-Ala-Phe (Leu-Ala-Phe). The tripeptide LAF disclosed by the invention has uric acid reducing activity for the first time, and the generation of uric acid can be reduced by reducing the activity of xanthine oxidase in the liver; meanwhile, uric acid discharge is increased by reducing kidney uric acid reabsorption. The invention provides an active substance for reducing uric acid through multi-target action, and the active substance can be applied to preparation of medicines for preventing or treating hyperuricemia or preparation of foods for assisting in reducing the uric acid level, and has a good application prospect.

The invention discloses application of lactobacillus rhamnosus HPT112 in preparation of a medicine for preventing and / or treating hyperuricemia, and belongs to the field of microorganisms, the lactobacillus rhamnosus HPT112 is preserved in the China Center for Type Culture Collection on November 20, 2023, and the preservation number is CCTCC NO: M20232273. Tests prove that the lactobacillus rhamnosus HPT112 has the function of regulating bile acid metabolism, so that the uric acid reducing effect is achieved, and the uric acid reducing effect equivalent to or even better than that of an existing hyperuricemia medicine can be achieved. Compared with existing hyperuricemia drugs, the lactobacillus rhamnosus HPT112 has the advantages that toxic and side effects are low, safety is high, a brand-new drug for preventing and / or treating hyperuricemia can be developed by the aid of the lactobacillus rhamnosus HPT112, and accordingly inflammatory reaction caused by hyperuricemia can be prevented and / or treated.

The invention discloses an intestinal strain capable of effectively regulating uric acid metabolism, a microbial agent of the intestinal strain and application of the intestinal strain in uric acid reducing products, and belongs to the technical field of microorganisms. According to the enterococcus pluvialis ZQ205, the enterococcus pluvialis ZQ205 which is free of toxic and side effects and capable of effectively relieving and treating the hyperuricemia is found for the first time, and the collection number of the enterococcus pluvialis ZQ205 in the China Center for Type Culture Collection is CCTCC NO: M 2025844; the strain can significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum of mice, can effectively reduce the levels of inflammatory factors such as IL-6 and TNF-alpha in serum of hyperuricemia mice, and can improve kidney injury caused by hyperuricemia.

The invention belongs to the technical field of microorganisms, and particularly relates to a lactobacillus casei M2b and application thereof.The lactobacillus casei M2b is preserved in the China Center for Type Culture Collection with the preservation number of CCTCC NO: M20221748, the lactobacillus casei M2b can remarkably reduce the blood uric acid level and the whole-body inflammation level of mice at the same time, liver and kidney injuries caused by hyperuricemia can be relieved, and the lactobacillus casei M2b has the advantages that the lactobacillus casei M2b can be used for preventing and treating hyperuricemia; the strain can be used for improving intestinal flora disorder of mice with hyperuricemia, can be used for preparing functional microbial agents or medicines for preventing or relieving hyperuricemia and related symptoms thereof, and has a wide application prospect.

The invention relates to a xanthine oxidase inhibitory peptide derived from green and sweet tuna and application of the xanthine oxidase inhibitory peptide, and belongs to the technical field of polypeptides, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Trp-Thr-Ala (WTA), Trp-Val-Pro (WVP), Trp-Leu-Pro (WLP) or Trp-Gly-Phe (WGF). The invention also provides an application of the inhibitory peptide as or in preparation of a xanthine oxidase inhibitor and an application of the inhibitory peptide as or in preparation of a medicine with an effect of inhibiting uric acid level. The invention also provides a xanthine oxidase inhibitor containing at least one inhibitory peptide or a composition or functional food for inhibiting uric acid. The selected inhibitory peptide is a novel food-borne XO inhibitory peptide, is good in water solubility, non-toxic and good in small intestine absorption and blood brain barrier permeability, has the potential of serving as a xanthine oxidase inhibitor and reducing the uric acid level, and can be used for preparing a medicine for preventing and treating hyperuricemia or serving as a functional food additive.

The invention belongs to the technical field of traditional Chinese medicines, and provides novel medical application of Chinese tamarisk twigs. The Chinese tamarisk twigs can be used for preparing medicines for preventing and treating hyperuricemia, and medicines for treating uric acid kidney stone, tophus or uric acid nephropathy caused by hyperuricemia. The invention also provides a preparation method of the Chinese tamarisk twig extract, which adopts water or / and ethanol for extraction. The new medical application of the Chinese tamarisk twigs is provided, the medical value of the Chinese tamarisk twigs is expanded, and compared with an existing uric acid reducing medicine allopurinol, the obtained extract can reduce the uric acid level of hyperuricemia, can inhibit rising of renal function indexes such as serum creatinine and urea nitrogen induced by hyperuricemia, improves liver and kidney tissue injuries, and has the advantages of being free of toxic and side effects, safe and reliable. The traditional Chinese medicine composition has the effect of improving liver and kidney functions and has good safety.

The invention discloses a plant lactobacillus and an application thereof in fermentation of sophora flowers for relieving hyperuricemia. The name of the lactobacillus plantarum is lactobacillus plantarum WH-JS4, the lactobacillus plantarum WH-JS4 is preserved in Guangdong Microbial Culture Collection Center on November 7, 2024, and the preservation number of the lactobacillus plantarum WH-JS4 is GDMCC No: 65437, the GDMCC No: 65437. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The lactobacillus plantarum WH-JS4 is named as lactobacillus plantarum WH-JS4. The plant lactobacillus WH-JS4 can be used for sophora flower fermentation, sophora flower fermentation liquor obtained through fermentation has a good uric acid reducing effect, and the plant lactobacillus WH-JS4 can be used for developing functional products for preventing or treating hyperuricemia.

The invention belongs to the field of biological medicine, and relates to application of an RINL antagonist in prevention and treatment of hyperuricemia. Specifically, the invention provides an application of an RINL gene or an encoding protein thereof, and the RINL gene or the encoding protein thereof: (1) is used as a marker for diagnosis, detection or prognosis of hyperuricemia; (2) preparing a reagent or a kit for diagnosing or detecting hyperuricemia; or (3) the compound is used for preparing a medicine for preventing and / or treating hyperuricemia. The RINL provided by the invention is an important related gene in the occurrence and development process of hyperuricemia, and is also a potential hyperuricemia treatment site. RINL expression is inhibited, and the uric acid excretion capacity of cells and mice is remarkably improved.

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.

The invention discloses a preparation method and application of a biomarker sensor for monitoring sweat gout. According to the scheme, an Au sensing electrode is prepared on the surface of a flexible polyethylene glycol terephthalate (PET) thin film in a patterning manner by utilizing an evaporation technology, and a polypyrrole functional layer is prepared on the surface of the electrode by virtue of a molecular imprinting technology; the gout biomarker high-sensitivity detection sensor is constructed in an efficient and rapid manner; the sensor can effectively identify uric acid and xanthine in sweat and display the concentration level of the uric acid and the xanthine, and can provide real-time sensing service for prevention of gout diseases and monitoring of diagnosis and treatment processes of patients with hyperuricemia and yellow urine diseases; a scanning electron microscope is used for carrying out microtopography characterization on the molecularly imprinted functional layer, and an electrochemical workstation is used for carrying out sensing recognition performance characterization. The sensor has the characteristics of rapid identification, convenient sensing and wide detection range for biomarkers of gout, hyperuricemia and yellow urine.

The invention discloses a preparation method and application of a medicinal and edible traditional Chinese medicine compound with an effect of treating uric acid diseases. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 15 to 25 parts of semen plantaginis, 15 to 25 parts of pawpaw, 5 to 15 parts of rhizoma smilacis glabrae, 5 to 15 parts of herba portulacae, 1 to 11 parts of radix glycyrrhizae preparata, 5 to 15 parts of folium mori, 5 to 15 parts of folium perillae, 1 to 11 parts of semen pruni, 5 to 15 parts of rhizoma polygonati, 1 to 11 parts of black dates and 1 to 9 parts of mulberries. The traditional Chinese medicine compound is composed of medicinal and edible raw materials, has stable efficacy of reducing uric acid and relieving uric acid liver and kidney injury, renal fibrosis and gouty arthritis, can relieve arthrocele caused by gout, reduces the level of joint inflammatory factors and the like, and takes effect quickly. The traditional Chinese medicine composition can be used for treating hyperuricemia, uric acid nephropathy, gouty arthritis and hyperuricemia accompanying symptoms.

The invention provides acid-resistant and cholate-resistant lactobacillus plantarum and application thereof, and relates to the technical field of microorganisms. The invention provides a strain with the capacity of degrading nucleic acid and inhibiting xanthine oxidase, namely lactobacillus plantarum HXJS3-1, and the lactobacillus plantarum HXJS3-1 has the effects of reducing the uric acid level and preventing and treating hyperuricemia and gout. In addition, the lactobacillus plantarum HXJS3-1 also has a certain anti-inflammatory effect and an effect of enhancing immunity. And a novel probiotic or medicine material is provided for treatment of hyperuricemia and related diseases thereof. The lactobacillus plantarum HXJS3-1 also has the characteristics of acid resistance, cholate resistance and no influence of existence of a carbon source and a nitrogen source, so that the lactobacillus plantarum HXJS3-1 can be widely applied to various scenes.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

The present invention belongs to the technical field of microorganisms and hyperuricemia disease prevention and treatment, and discloses a plant lactobacillus with uric acid lowering effect, a microcapsule, a preparation method and an application thereof, which is named SHS01, and the classification name is: plant lactobacillus (Lactobacillus plantarum), the deposit number is: CGMCC No.31000, the deposit date is: June 19, 2024, and the deposit unit is: General Microbiological Center of China Microbiological Culture Collection Administration Committee, No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing. In the in vitro degradation, the plant lactobacillus SHS01 of the present invention has a degradation rate of 89.44% for inosine and a degradation rate of 100% for guanosine. Therefore, as a plant lactobacillus that can efficiently degrade nucleosides in vitro, it has broad application prospects in lowering uric acid.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

The invention belongs to the field of biological medicine, and particularly relates to application of urolithin D in preparation of medicine for relieving hyperuricemia. It is found for the first time that the urolithin D can significantly reduce the level of serum uric acid, improve the expression disorder of a kidney urate transporter, efficiently relieve or treat hyperuricemia and related diseases thereof, and relieve kidney injury and fibrosis; and the compound can be used for preparing medicines for treating hyperuricemia and related diseases, is low in cost and good in safety, and has a wide application prospect.

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.

The present invention relates to the field of Chinese medicinal materials, and in particular to a Chinese medicine composition, a medicine, and a preparation method and application thereof for treating hyperuricemia with hyperlipidemia. The Chinese medicine composition and medicine provided by the present invention can intervene in the treatment of asymptomatic hyperuricemia combined with hyperlipidemia, and compared with traditional uric acid-lowering drugs (febuxostat), serum uric acid can be quickly reduced, and the uric acid level can be basically controlled within a normal range. No gout symptoms are found in patients within 6 months of treatment, and complications such as hypertension, hyperglycemia, and cardiovascular and cerebrovascular diseases can be significantly reduced, and the quality of life of patients can be improved; it can also overcome the technical deficiencies of uric acid-lowering drugs, such as many adverse reactions, difficult to sustain therapeutic effects, and limited applicable populations, and has the advantages of small side effects, long-lasting efficacy, and multiple drug targets.

The invention belongs to the technical field of biological medicines, and particularly relates to a cordyceps sobolifera fermentation extract for reducing uric acid as well as a preparation method and application of the cordyceps sobolifera fermentation extract. The method comprises the following steps: concentrating cordyceps sobolifera fungus fermentation liquor, then leaching with ethanol, concentrating leaching liquor, then sequentially extracting with n-butyl alcohol, ethyl acetate and petroleum ether, and concentrating extracts to respectively obtain an n-butyl alcohol extraction part, an ethyl acetate extraction part, a petroleum ether extraction part and a residual part, the obtained petroleum ether extract is the cordyceps sobolifera fermentation extract for reducing uric acid. The cordyceps sobolifera fermentation extract disclosed by the invention has the effects of remarkably relieving kidney injury of a mouse with hyperuricemia and reducing serum uric acid of the mouse with hyperuricemia. As a novel natural uric acid-reducing active substance, the cordyceps sobolifera fermentation extract disclosed by the invention can be applied to the fields of health foods and medicines, and has good development and application values.

The invention discloses application of compounds in preparation of anti-hyperuricemia drugs, and the compounds are proved to be capable of reducing serum UA, Cr and BUN levels of a hyperuricemia mouse model to different degrees, relieving kidney injury and protecting renal functions, so that the compounds can be applied to the drugs for preventing, treating or relieving hyperuricemia, and the application of the compounds in preparation of the anti-hyperuricemia drugs in preparation of the anti-hyperuricemia drugs in preparation of the anti-hyperuricemia drugs in preparation of the anti-hyperuricemia drugs in preparation of the anti-hyperuricemia drugs. The traditional Chinese medicine composition can be used for treating gout and gout complications caused by hyperuricemia.

The invention relates to the technical field of medicine, in particular to application of 5-bromocytidine in medicine for treating hyperuricemia, the 5-bromocytidine can effectively reduce the content of uric acid in serum, namely, the 5-bromocytidine has the effect of treating the hyperuricemia.

The invention relates to lactobacillus reuteri SAU-R-8 which is derived from Tibet naturally-fermented sour yak milk and is used for producing exopolysaccharides and application of the lactobacillus reuteri SAU-R-8 in reducing uric acid, and belongs to the technical field of microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30373, and the preservation date is April 19, 2024. The lactobacillus reuteri SAU-R-8 provided by the invention is screened from yak yogurt naturally fermented from herdsmen in the Sankarst region of Tibet, the yield of exopolysaccharides in an MRS culture medium reaches 318.57 mg / L, nucleoside substances such as inosine and guanosine can be efficiently degraded, purine substances such as guanine can be efficiently absorbed, the activity of xanthine oxidase can be inhibited, and the lactobacillus reuteri SAU-R-8 can be used for preparing the yak yogurt. The method can be further applied to product development for relieving or treating hyperuricemia.

The invention discloses a novel application of Wickerhamomyces anomalus YFJ252 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28267) which is disclosed and preserved, in particular relates to an application of the strain and a metabolite of the strain in preparation of medicines, foods or health care products for preventing or treating hyperuricemia (HUA), and belongs to the technical field of microorganisms. The strain has excellent probiotic characteristics (acid and cholate resistance, high hydrophobicity, self-aggregation and co-aggregation capability, oxidation resistance, glycometabolism regulation, anti-inflammatory capability and the like) and a function of inhibiting the activity of xanthine oxidase (XO) in vitro. The serum uric acid, creatinine and urea nitrogen levels of a hyperuricemia mouse model induced by high fructose diet and oteracil potassium can be remarkably controlled, and a new way is provided for safely and effectively preventing HUA.